JP2018507207A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2018507207A5 JP2018507207A5 JP2017543772A JP2017543772A JP2018507207A5 JP 2018507207 A5 JP2018507207 A5 JP 2018507207A5 JP 2017543772 A JP2017543772 A JP 2017543772A JP 2017543772 A JP2017543772 A JP 2017543772A JP 2018507207 A5 JP2018507207 A5 JP 2018507207A5
- Authority
- JP
- Japan
- Prior art keywords
- fluorobiphenyl
- chloro
- amino
- compound
- item
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 150000001875 compounds Chemical class 0.000 claims description 31
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 claims description 12
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 claims description 12
- 208000017169 kidney disease Diseases 0.000 claims description 11
- 238000004519 manufacturing process Methods 0.000 claims description 10
- 239000006186 oral dosage form Substances 0.000 claims description 10
- 239000007787 solid Substances 0.000 claims description 10
- 206010019280 Heart failures Diseases 0.000 claims description 9
- 206010020772 Hypertension Diseases 0.000 claims description 9
- RRCIEZCEOIRHEB-VQIMIIECSA-N (2R,4R)-5-[4-(5-chloro-2-fluorophenyl)phenyl]-2-hydroxy-4-[(5-methyl-1,3-oxazole-2-carbonyl)amino]pentanoic acid Chemical compound ClC=1C=CC(=C(C=1)C1=CC=C(C=C1)C[C@H](C[C@H](C(=O)O)O)NC(=O)C=1OC(=CN=1)C)F RRCIEZCEOIRHEB-VQIMIIECSA-N 0.000 claims description 8
- -1 7-azabenzotriazol-1-yl Chemical group 0.000 claims description 8
- 238000000034 method Methods 0.000 claims description 7
- 102000002723 Atrial Natriuretic Factor Human genes 0.000 claims description 6
- 101800001288 Atrial natriuretic factor Proteins 0.000 claims description 6
- 101800001890 Atrial natriuretic peptide Proteins 0.000 claims description 6
- WMFOQBRAJBCJND-UHFFFAOYSA-M Lithium hydroxide Chemical compound [Li+].[OH-] WMFOQBRAJBCJND-UHFFFAOYSA-M 0.000 claims description 6
- 239000002775 capsule Substances 0.000 claims description 6
- NSQLIUXCMFBZME-MPVJKSABSA-N carperitide Chemical compound C([C@H]1C(=O)NCC(=O)NCC(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@H](C(NCC(=O)N[C@@H](C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H](CC(C)C)C(=O)NCC(=O)N[C@@H](CSSC[C@@H](C(=O)N1)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](N)CO)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(O)=O)=O)[C@@H](C)CC)C1=CC=CC=C1 NSQLIUXCMFBZME-MPVJKSABSA-N 0.000 claims description 6
- 239000013078 crystal Substances 0.000 claims description 6
- ZOOGRGPOEVQQDX-KHLHZJAASA-N cyclic guanosine monophosphate Chemical compound C([C@H]1O2)O[P@](O)(=O)O[C@@H]1[C@H](O)[C@H]2N1C(N=C(NC2=O)N)=C2N=C1 ZOOGRGPOEVQQDX-KHLHZJAASA-N 0.000 claims description 6
- 239000003937 drug carrier Substances 0.000 claims description 6
- WDBBEKDVFVFYRC-CRAIPNDOSA-N ethyl (2r,4r)-4-amino-5-[4-(5-chloro-2-fluorophenyl)phenyl]-2-hydroxypentanoate Chemical compound C1=CC(C[C@@H](N)C[C@@H](O)C(=O)OCC)=CC=C1C1=CC(Cl)=CC=C1F WDBBEKDVFVFYRC-CRAIPNDOSA-N 0.000 claims description 6
- 239000008194 pharmaceutical composition Substances 0.000 claims description 6
- HGZMWZLQUPTYSX-UHFFFAOYSA-N 2-methyl-3H-1,3-oxazole-2-carboxylic acid Chemical compound CC1(OC=CN1)C(=O)O HGZMWZLQUPTYSX-UHFFFAOYSA-N 0.000 claims description 4
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 4
- 108010010803 Gelatin Proteins 0.000 claims description 4
- JGFZNNIVVJXRND-UHFFFAOYSA-N N,N-Diisopropylethylamine (DIPEA) Chemical compound CCN(C(C)C)C(C)C JGFZNNIVVJXRND-UHFFFAOYSA-N 0.000 claims description 4
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 claims description 4
- 102000004861 Phosphoric Diester Hydrolases Human genes 0.000 claims description 4
- 108090001050 Phosphoric Diester Hydrolases Proteins 0.000 claims description 4
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 claims description 4
- 238000000113 differential scanning calorimetry Methods 0.000 claims description 4
- 238000004090 dissolution Methods 0.000 claims description 4
- 229920000159 gelatin Polymers 0.000 claims description 4
- 239000008273 gelatin Substances 0.000 claims description 4
- 235000019322 gelatine Nutrition 0.000 claims description 4
- 235000011852 gelatine desserts Nutrition 0.000 claims description 4
- 150000004676 glycans Chemical class 0.000 claims description 4
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical group [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 claims description 4
- 229920001282 polysaccharide Polymers 0.000 claims description 4
- 239000005017 polysaccharide Substances 0.000 claims description 4
- 238000000634 powder X-ray diffraction Methods 0.000 claims description 4
- 238000003756 stirring Methods 0.000 claims description 4
- 229920001059 synthetic polymer Polymers 0.000 claims description 4
- NQPDZGIKBAWPEJ-UHFFFAOYSA-N valeric acid Chemical compound CCCCC(O)=O NQPDZGIKBAWPEJ-UHFFFAOYSA-N 0.000 claims description 4
- 239000003814 drug Substances 0.000 claims description 3
- 208000002815 pulmonary hypertension Diseases 0.000 claims description 3
- 239000005541 ACE inhibitor Substances 0.000 claims description 2
- 101710129690 Angiotensin-converting enzyme inhibitor Proteins 0.000 claims description 2
- 101710086378 Bradykinin-potentiating and C-type natriuretic peptides Proteins 0.000 claims description 2
- 229920001661 Chitosan Polymers 0.000 claims description 2
- 239000007821 HATU Substances 0.000 claims description 2
- 239000002333 angiotensin II receptor antagonist Substances 0.000 claims description 2
- 239000000400 angiotensin II type 1 receptor blocker Substances 0.000 claims description 2
- 229940044094 angiotensin-converting-enzyme inhibitor Drugs 0.000 claims description 2
- 239000007864 aqueous solution Substances 0.000 claims description 2
- 238000004587 chromatography analysis Methods 0.000 claims description 2
- 208000020832 chronic kidney disease Diseases 0.000 claims description 2
- 238000010276 construction Methods 0.000 claims description 2
- 238000013270 controlled release Methods 0.000 claims description 2
- 230000003111 delayed effect Effects 0.000 claims description 2
- 239000002934 diuretic Substances 0.000 claims description 2
- 230000001882 diuretic effect Effects 0.000 claims description 2
- 230000024924 glomerular filtration Effects 0.000 claims description 2
- 239000007902 hard capsule Substances 0.000 claims description 2
- 238000010438 heat treatment Methods 0.000 claims description 2
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 claims description 2
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 claims description 2
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 claims description 2
- UFVKGYZPFZQRLF-UHFFFAOYSA-N hydroxypropyl methyl cellulose Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC2C(C(O)C(OC3C(C(O)C(O)C(CO)O3)O)C(CO)O2)O)C(CO)O1 UFVKGYZPFZQRLF-UHFFFAOYSA-N 0.000 claims description 2
- 239000012729 immediate-release (IR) formulation Substances 0.000 claims description 2
- 239000003112 inhibitor Substances 0.000 claims description 2
- 239000006207 intravenous dosage form Substances 0.000 claims description 2
- 239000007788 liquid Substances 0.000 claims description 2
- 235000019359 magnesium stearate Nutrition 0.000 claims description 2
- 239000000463 material Substances 0.000 claims description 2
- 239000000843 powder Substances 0.000 claims description 2
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims description 2
- 239000002461 renin inhibitor Substances 0.000 claims description 2
- 229940086526 renin-inhibitors Drugs 0.000 claims description 2
- 150000003839 salts Chemical class 0.000 claims description 2
- VIIDTFSZAWAMNW-UHFFFAOYSA-M sodium 5-methyl-1,3-oxazole-2-carboxylate Chemical compound CC1=CN=C(O1)C(=O)[O-].[Na+] VIIDTFSZAWAMNW-UHFFFAOYSA-M 0.000 claims description 2
- 239000000725 suspension Substances 0.000 claims description 2
- 239000003826 tablet Substances 0.000 claims description 2
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 claims description 2
- 238000002560 therapeutic procedure Methods 0.000 claims description 2
- 210000002700 urine Anatomy 0.000 claims description 2
- 125000005500 uronium group Chemical group 0.000 claims description 2
- 239000000203 mixture Substances 0.000 claims 8
- 208000001647 Renal Insufficiency Diseases 0.000 claims 1
- 201000006370 kidney failure Diseases 0.000 claims 1
- 102000003729 Neprilysin Human genes 0.000 description 2
- 108090000028 Neprilysin Proteins 0.000 description 2
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 206010062237 Renal impairment Diseases 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 229940124597 therapeutic agent Drugs 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201562118067P | 2015-02-19 | 2015-02-19 | |
| US62/118,067 | 2015-02-19 | ||
| PCT/US2016/017699 WO2016133803A1 (en) | 2015-02-19 | 2016-02-12 | (2r,4r)-5-(5'-chloro-2'-fluorobiphenyl-4-yl)-2-hydroxy-4-[(5-methyloxazole-2-carbonyl)amino]pentanoic acid |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2018507207A JP2018507207A (ja) | 2018-03-15 |
| JP2018507207A5 true JP2018507207A5 (enExample) | 2019-02-14 |
| JP6714009B2 JP6714009B2 (ja) | 2020-06-24 |
Family
ID=55456914
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017543772A Active JP6714009B2 (ja) | 2015-02-19 | 2016-02-12 | （２ｒ，４ｒ）−５−（５’−クロロ−２’−フルオロビフェニル−４−イル）−２−ヒドロキシ−４−［（５−メチルオキサゾール−２−カルボニル）アミノ］ペンタン酸 |
Country Status (29)
| Country | Link |
|---|---|
| US (6) | US9533962B2 (enExample) |
| EP (1) | EP3259255B1 (enExample) |
| JP (1) | JP6714009B2 (enExample) |
| KR (1) | KR102573351B1 (enExample) |
| CN (1) | CN107250119B (enExample) |
| AU (1) | AU2016220348B2 (enExample) |
| BR (1) | BR112017017783A2 (enExample) |
| CA (1) | CA2975269C (enExample) |
| CO (1) | CO2017008426A2 (enExample) |
| CY (1) | CY1123728T1 (enExample) |
| DK (1) | DK3259255T3 (enExample) |
| ES (1) | ES2857101T3 (enExample) |
| HR (1) | HRP20210040T1 (enExample) |
| HU (1) | HUE052732T2 (enExample) |
| IL (1) | IL253759B (enExample) |
| LT (1) | LT3259255T (enExample) |
| MX (1) | MX370065B (enExample) |
| MY (1) | MY191183A (enExample) |
| PH (1) | PH12017501444A1 (enExample) |
| PL (1) | PL3259255T3 (enExample) |
| PT (1) | PT3259255T (enExample) |
| RS (1) | RS61325B1 (enExample) |
| RU (1) | RU2715241C2 (enExample) |
| SG (1) | SG11201706662YA (enExample) |
| SI (1) | SI3259255T1 (enExample) |
| SM (1) | SMT202100028T1 (enExample) |
| TW (1) | TWI707846B (enExample) |
| WO (1) | WO2016133803A1 (enExample) |
| ZA (1) | ZA201705487B (enExample) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| RS55967B1 (sr) * | 2012-06-08 | 2017-09-29 | Theravance Biopharma R&D Ip Llc | Inhibitori neprilizina |
| PL3259255T3 (pl) | 2015-02-19 | 2021-07-26 | Theravance Biopharma R&D Ip, Llc | Kwas (2R,4R)-5-(5'-chloro-2'-fluorobifenyl-4-ilo)-2-hydroksy-4-[(5-metylooksazolo-2-karbonylo)amino]pentanowy |
| KR102238177B1 (ko) | 2017-09-15 | 2021-04-07 | 주식회사 엘지화학 | 전지셀 및 전극 리드 제조방법 |
| UY38072A (es) | 2018-02-07 | 2019-10-01 | Novartis Ag | Compuestos derivados de éster butanoico sustituido con bisfenilo como inhibidores de nep, composiciones y combinaciones de los mismos |
| EP3994134B9 (en) * | 2019-07-03 | 2024-06-26 | Merck Patent GmbH | Process for manufacturing (s)-3-hydroxy-1-(1h-indol-5-yl)-2-oxo-pyrrolidine-3-carboxylic acid 3,5-difluoro-benzylamide |
Family Cites Families (50)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4189604A (en) | 1975-07-22 | 1980-02-19 | Zaidan Hojin Biseibutsu Kagaku Kenkyu Kai | Bestatin |
| US4206232A (en) | 1976-05-10 | 1980-06-03 | E. R. Squibb & Sons, Inc. | Relieving hypertension with carboxyalkylacylamino acids |
| IL58849A (en) | 1978-12-11 | 1983-03-31 | Merck & Co Inc | Carboxyalkyl dipeptides and derivatives thereof,their preparation and pharmaceutical compositions containing them |
| FR2480747A1 (fr) | 1980-04-17 | 1981-10-23 | Roques Bernard | Derives d'acides amines et leur application therapeutique |
| US4906615A (en) | 1980-12-18 | 1990-03-06 | Schering Corporation | Substituted dipeptides as inhibitors of enkephalinases |
| US4722810A (en) | 1984-08-16 | 1988-02-02 | E. R. Squibb & Sons, Inc. | Enkephalinase inhibitors |
| US4939261A (en) | 1984-06-08 | 1990-07-03 | Ciba-Geigy Corporation | N-substituted butyramide derivatives useful for treatment of conditions responsive to inhibition of enkephalinase |
| EP0225292A3 (en) | 1985-12-06 | 1988-11-30 | Ciba-Geigy Ag | Certain n-substituted butyramide derivatives |
| US4929641B1 (en) | 1988-05-11 | 1994-08-30 | Schering Corp | Mercapto-acylamino acid antihypertensives |
| KR880007441A (ko) | 1986-12-11 | 1988-08-27 | 알렌 제이.스피겔 | 스피로-치환된 글루타르아미드 이뇨제 |
| FR2623498B1 (fr) | 1987-11-24 | 1990-04-06 | Bioprojet Soc Civ | Nouveaux composes enantiomeres derives d'amino-acides, leur procede de preparation et leurs applications therapeutiques |
| GB8820844D0 (en) | 1988-09-05 | 1988-10-05 | Pfizer Ltd | Therapeutic agents |
| US5599951A (en) | 1989-09-15 | 1997-02-04 | Societe Civile Bioprojet | Amino acid derivatives, the process for their preparation and their applications to therapy |
| US5155100A (en) | 1991-05-01 | 1992-10-13 | Ciba-Geigy Corporation | Phosphono/biaryl substituted dipeptide derivatives |
| US5294632A (en) | 1991-05-01 | 1994-03-15 | Ciba-Geigy Corporation | Phosphono/biaryl substituted dipetide derivatives |
| US5217996A (en) | 1992-01-22 | 1993-06-08 | Ciba-Geigy Corporation | Biaryl substituted 4-amino-butyric acid amides |
| US5508272A (en) | 1993-06-15 | 1996-04-16 | Bristol-Myers Squibb Company | Compounds containing a fused bicycle ring and processes therefor |
| DE19510566A1 (de) | 1995-03-23 | 1996-09-26 | Kali Chemie Pharma Gmbh | Benzazepin-, Benzoxazepin- und Benzothiazepin-N-essigsäurederivate sowie Verfahren zu ihrer Herstellung und diese Verbindungen enthaltende Arzneimittel |
| WO1996033170A1 (en) | 1995-04-21 | 1996-10-24 | Novarits Ag | N-aroylamino acid amides as endothelin inhibitors |
| US6660756B2 (en) | 2001-03-28 | 2003-12-09 | Pfizer Inc. | N-phenpropylcyclopentyl-substituted glutaramide derivatives as inhibitors of neutral endopeptidase |
| GB0119305D0 (en) | 2001-04-12 | 2001-10-03 | Aventis Pharma Gmbh | Mercaptoacetylamide derivatives,a process for their preparation and their use |
| WO2006027680A1 (en) | 2004-09-10 | 2006-03-16 | Pfizer Limited | 3-(1-carbamoylcyclohexyl) propionic acid derivatives as inhibitors of neutral endopeptidase enzyme |
| AR057882A1 (es) | 2005-11-09 | 2007-12-26 | Novartis Ag | Compuestos de accion doble de bloqueadores del receptor de angiotensina e inhibidores de endopeptidasa neutra |
| WO2007106708A2 (en) | 2006-03-10 | 2007-09-20 | Novartis Ag | Combinations of the angiotensin ii antagonist valsartan and the nep inhibitor daglutril |
| BRPI0806700A8 (pt) | 2007-01-12 | 2019-01-22 | Novartis Ag | processo |
| TWI448284B (zh) | 2007-04-24 | 2014-08-11 | Theravance Inc | 雙效抗高血壓劑 |
| AR070176A1 (es) | 2008-01-17 | 2010-03-17 | Novartis Ag | Procesos de sintesis de inhibidores de nep, compuestos intermediarios y uso de los mismos en la sintesis |
| CN102574801B (zh) | 2009-05-28 | 2016-04-27 | 诺华股份有限公司 | 作为脑啡肽酶抑制剂的取代的氨基丙酸衍生物 |
| CN102448928B (zh) * | 2009-05-28 | 2014-10-01 | 诺华股份有限公司 | 作为中性溶酶(neprilysin)抑制剂的取代的氨基丁酸衍生物 |
| WO2011011232A1 (en) * | 2009-07-22 | 2011-01-27 | Theravance, Inc. | Dual-acting oxazole antihypertensive agents |
| JO2967B1 (en) | 2009-11-20 | 2016-03-15 | نوفارتس ايه جي | Acetic acid derivatives of carbamoyl methyl amino are substituted as new NEP inhibitors |
| BR112012017869A2 (pt) | 2010-01-22 | 2019-09-24 | Novartis Ag | "intermediários dos inibidores da endopeptidase neutraq e método de preparação dos mesmos" |
| US8673974B2 (en) | 2010-11-16 | 2014-03-18 | Novartis Ag | Substituted amino bisphenyl pentanoic acid derivatives as NEP inhibitors |
| US8993631B2 (en) | 2010-11-16 | 2015-03-31 | Novartis Ag | Method of treating contrast-induced nephropathy |
| AR084290A1 (es) | 2010-12-15 | 2013-05-08 | Theravance Inc | Inhibidores de neprilisina, metodos para su preparacion e intermediarios utilizados en los mismos, composiciones farmaceuticas que los comprenden y su uso en la fabricacion de medicamentos para tratar enfermedades mediadas por la inhibicion de nep |
| CN105061314A (zh) | 2010-12-15 | 2015-11-18 | 施万生物制药研发Ip有限责任公司 | 脑啡肽酶抑制剂 |
| JP5959065B2 (ja) | 2011-02-17 | 2016-08-02 | セラヴァンス バイオファーマ アール＆ディー アイピー， エルエルシー | ネプリライシン阻害剤としての置換アミノ酪酸誘導体 |
| JP5959066B2 (ja) | 2011-02-17 | 2016-08-02 | セラヴァンス バイオファーマ アール＆ディー アイピー， エルエルシー | ネプリライシン阻害剤としての置換アミノ酪酸誘導体 |
| EP2714660B1 (en) | 2011-05-31 | 2018-09-26 | Theravance Biopharma R&D IP, LLC | Neprilysin inhibitors |
| ES2653215T3 (es) | 2011-05-31 | 2018-02-06 | Theravance Biopharma R&D Ip, Llc | Inhibidores de neprilisina |
| WO2012166389A1 (en) | 2011-05-31 | 2012-12-06 | Theravance, Inc. | Neprilysin inhibitors |
| TWI560172B (en) | 2011-11-02 | 2016-12-01 | Theravance Biopharma R&D Ip Llc | Neprilysin inhibitors |
| JP6088047B2 (ja) | 2012-05-31 | 2017-03-01 | セラヴァンス バイオファーマ アール＆ディー アイピー， エルエルシー | 一酸化窒素ドナーであるネプリライシン阻害剤 |
| RS55967B1 (sr) | 2012-06-08 | 2017-09-29 | Theravance Biopharma R&D Ip Llc | Inhibitori neprilizina |
| EP2858650B1 (en) | 2012-06-08 | 2018-11-14 | Theravance Biopharma R&D IP, LLC | Neprilysin inhibitors |
| PL2882716T3 (pl) | 2012-08-08 | 2017-06-30 | Theravance Biopharma R&D Ip, Llc | Inhibitory neprylizyny |
| RS56300B1 (sr) | 2013-03-05 | 2017-12-29 | Theravance Biopharma R&D Ip Llc | Inhibitori neprilizina |
| RU2016135057A (ru) * | 2014-01-30 | 2018-03-12 | ТЕРЕВАНС БАЙОФАРМА Ар энд Ди АйПи, ЭлЭлСи | Производные 5-бифенил-4-гетероарилкарбониламинопентановой кислоты в качестве ингибиторов неприлизина |
| KR102640906B1 (ko) | 2015-02-11 | 2024-02-27 | 세라밴스 바이오파마 알앤디 아이피, 엘엘씨 | 네프릴리신 저해제로서 (2s,4r)-5-(5''-클로로-2''-플루오로비페닐-4-일)-4-(에톡시옥살릴아미노)-2-히드록시메틸-2-메틸펜타노익산 |
| PL3259255T3 (pl) | 2015-02-19 | 2021-07-26 | Theravance Biopharma R&D Ip, Llc | Kwas (2R,4R)-5-(5'-chloro-2'-fluorobifenyl-4-ilo)-2-hydroksy-4-[(5-metylooksazolo-2-karbonylo)amino]pentanowy |
-
2016
- 2016-02-12 PL PL16708268T patent/PL3259255T3/pl unknown
- 2016-02-12 HR HRP20210040TT patent/HRP20210040T1/hr unknown
- 2016-02-12 MY MYPI2017702772A patent/MY191183A/en unknown
- 2016-02-12 EP EP16708268.4A patent/EP3259255B1/en active Active
- 2016-02-12 DK DK16708268.4T patent/DK3259255T3/da active
- 2016-02-12 RU RU2017132430A patent/RU2715241C2/ru active
- 2016-02-12 LT LTEP16708268.4T patent/LT3259255T/lt unknown
- 2016-02-12 ES ES16708268T patent/ES2857101T3/es active Active
- 2016-02-12 PT PT167082684T patent/PT3259255T/pt unknown
- 2016-02-12 BR BR112017017783-8A patent/BR112017017783A2/pt not_active Application Discontinuation
- 2016-02-12 US US15/042,391 patent/US9533962B2/en active Active
- 2016-02-12 HU HUE16708268A patent/HUE052732T2/hu unknown
- 2016-02-12 SM SM20210028T patent/SMT202100028T1/it unknown
- 2016-02-12 MX MX2017010666A patent/MX370065B/es active IP Right Grant
- 2016-02-12 JP JP2017543772A patent/JP6714009B2/ja active Active
- 2016-02-12 WO PCT/US2016/017699 patent/WO2016133803A1/en not_active Ceased
- 2016-02-12 CA CA2975269A patent/CA2975269C/en active Active
- 2016-02-12 AU AU2016220348A patent/AU2016220348B2/en not_active Ceased
- 2016-02-12 SI SI201631051T patent/SI3259255T1/sl unknown
- 2016-02-12 KR KR1020177026454A patent/KR102573351B1/ko active Active
- 2016-02-12 CN CN201680011254.0A patent/CN107250119B/zh not_active Expired - Fee Related
- 2016-02-12 RS RS20210057A patent/RS61325B1/sr unknown
- 2016-02-12 SG SG11201706662YA patent/SG11201706662YA/en unknown
- 2016-02-19 TW TW105104991A patent/TWI707846B/zh active
- 2016-11-21 US US15/357,269 patent/US9872855B2/en active Active
-
2017
- 2017-07-31 IL IL253759A patent/IL253759B/en active IP Right Grant
- 2017-08-10 PH PH12017501444A patent/PH12017501444A1/en unknown
- 2017-08-14 ZA ZA2017/05487A patent/ZA201705487B/en unknown
- 2017-08-18 CO CONC2017/0008426A patent/CO2017008426A2/es unknown
- 2017-12-14 US US15/841,799 patent/US10172834B2/en active Active
-
2018
- 2018-12-03 US US16/207,501 patent/US10548879B2/en active Active
-
2019
- 2019-12-16 US US16/715,722 patent/US11033533B2/en not_active Expired - Fee Related
-
2021
- 2021-01-20 CY CY20211100045T patent/CY1123728T1/el unknown
- 2021-05-14 US US17/302,877 patent/US11642332B2/en active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| TWI826416B (zh) | 趨化介素受體調節劑及其用途 | |
| JP2018507207A5 (enExample) | ||
| TWI548630B (zh) | １－（３－氰基－１－異丙基－吲哚－５－基）吡唑－４－羧酸結晶型及其製造方法 | |
| TWI657826B (zh) | Complex of angiotensin II receptor antagonist metabolite and NEP inhibitor and preparation method thereof | |
| JP2020508338A5 (enExample) | ||
| JP2018506535A5 (ja) | ネプリライシン阻害剤としての（２ｓ，４ｒ）−５−（５’−クロロ−２’−フルオロビフェニル−４−イル）−４−（エトキシオキサリルアミノ）−２−ヒドロキシメチル−２−メチルペンタン酸 | |
| TW201011003A (en) | Triazole compounds that modulate HSP90 activity | |
| JP2022191265A (ja) | 錠剤組成物 | |
| EA039829B1 (ru) | Комбинированная терапия для лечения злокачественных опухолей | |
| TW200412970A (en) | Pharmaceutical composition comprising PDE 5 inhibitor and active ingredients | |
| JP2016509031A (ja) | トレラグリプチンの固形形式及びその製造方法と用途 | |
| TW200845998A (en) | Heterocyclic compounds useful in treating diseases and conditions | |
| RU2017132430A (ru) | (2r,4r)-5-(5′-хлор-2′-фторбифенил-4-ил)-2-гидрокси-4-[(5-метилоксазол-2-карбонил)амино]пентановая кислота | |
| RU2017131522A (ru) | (2s,4r)-5-(5'-хлор-2'-фторбифенил-4-ил)-2-этоксиоксалиламино)-)-2-гидроксиметил-2-метилпентановая кислота | |
| JP5202302B2 (ja) | 医薬組成物 | |
| WO2016051393A2 (en) | Crystalline form iv of trisodium supramolecular complex comprising valsartan and ahu-377 and methods thereof | |
| US11883423B2 (en) | Nucleobase analogue derivatives and their applications | |
| AU2020221247B2 (en) | Formulations comprising heterocyclic protein kinase inhibitors | |
| US10947225B2 (en) | Phosphotidylinositol 3-kinase inhibitors | |
| CN120324424A (zh) | 8-氯-n-(4-(三氟甲氧基)苯基)喹啉-2-胺的无定形固体分散体 | |
| US12030861B1 (en) | L-lysine salt of 4-chloro-5-[4-(2,6-dichlorophenyl)sulfonylpiperazin-1-yl]-1-benzofuran-2-carboxylic acid and various forms thereof | |
| JP7160043B2 (ja) | 結晶 | |
| RU2018135072A (ru) | Кристаллическая (2s,4r)-5-(5'-хлор-2'-фтор-[1,1'-бифенил]-4-ил)-2-(этоксиметил)-4-(3-гидроксиизоксазол-5-карбоксамидо)-2-метилпентановая кислота и ее применения | |
| JP2019509286A5 (enExample) | ||
| TWI285110B (en) | Parkinson disease therapeutic agent |